

Characterization of vaccine-breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community in France

François Blanquart, Clémence Abad, Joevin Ambroise, Mathieu Bernard, Gina Cosentino, Jean-Marc Giannoli, Florence Débarre

▶ To cite this version:

François Blanquart, Clémence Abad, Joevin Ambroise, Mathieu Bernard, Gina Cosentino, et al.. Characterization of vaccine-breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community in France. 2021. hal-03318483v2

HAL Id: hal-03318483 https://hal.sorbonne-universite.fr/hal-03318483v2

Preprint submitted on 15 Aug 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Characterization of vaccine-breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community in France

François Blanquart^{1,2 *} Clér

Clémence Abad³

Joevin Ambroise⁴

Mathieu Bernard⁵ Gina Cosentino^{4,6}

.

Jean-Marc Giannoli⁷

Florence Débarre⁸**

2021-08-15

1. Infection Antimicrobials Modelling Evolution, UMR1137, INSERM, Université de Paris, Paris, France

2. Centre for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS, INSERM, PSL Research University, Paris, France

3. LBM BIOESTEREL-Biogroup-Plateau technique de Mouans-Sartoux, Mouans-Sartoux, France

4. BPO-BIOEPINE–Biogroup–Plateau technique Chocolaterie, Levallois-Perret, France

5. BIOLITTORAL – Biogroup – Plateau technique la Bastide, Sanary sur Mer, France

6. UMR1173 INSERM, UniversitéParis-Saclay–UVSQ, Montigny-le-Bretonneux, France

7. DYOMEDEA-NEOLAB-Biogroup – Plateau technique de la Sauvegarde, Lyon 9 France

8. Institute of Ecology and Environmental Sciences of Paris (iEES-Paris, UMR 7618), CNRS, Sorbonne Université, UPEC, IRD, INRAE, 75252 Paris, France

*francois.blanquart@college-de-france.fr **florence.debarre@normalesup.org

Abstract: We compare test results of SARS-CoV-2 positive patients, depending on their vaccine status,

² the presence of symptoms and whether they are infected by the Delta variant or not, using a large num-

³ ber of PCR tests done in the community in France from 14 June 2021 to 30 July 2021. In asymptomatic

⁴ individuals, Ct values at the first positive test were higher in fully vaccinated individuals (> 2 weeks after

⁵ final dose) than non fully vaccinated individuals (1.7 [1, 2.3], *p* < 1e-6). In *symptomatic* individuals

⁶ however, Ct values at the time of symptoms were not significantly different in vaccinated compared

 τ to unvaccinated individuals (p = 0.26). This was true both for infections by Delta and non-Delta

⁸ (essentially Alpha in France at the time) variants. These results suggest that some infected vaccinated

⁹ individuals, especially if symptomatic, may transmit the virus as much as unvaccinated individuals.

10

The SARS-CoV-2 variant of concern Delta, first detected in India, spread across the world in 2021, and in particular in Europe in late spring – early summer 2021, where it displaced the previously dominant Alpha variant. Delta was shown to be fitter than Alpha,¹⁻³ and may be associated with higher virulence⁴⁻⁶ and lesser vaccine effectiveness^{6,7} against symptomatic disease, especially after just one dose.

¹⁶ Delta has spread in countries with high vaccination levels, and breakthrough infections have been

¹⁷ reported, with Ct values suggesting similar viral loads between vaccinated and unvaccinated infected

 $_{18}$ individuals. $^{8-10}$ A longitudinal study has confirmed similar Ct values between Delta-infected vaccinated

- ¹⁹ and unvaccinated patients in the first week after diagnosis or symptom onset, with later faster decline
- ²⁰ in vaccinated patients.¹¹ Comparisons of Ct values in infections with Delta compared to infections
- ²¹ with previous variants require controlling for infection age when variants has different epidemiological
- ²² dynamics. This is because viral load depends on infection age, and the distribution of infection ages
- ²³ depends on whether the number of cases is growing or shrinking.^{12–16}
- ²⁴ We studied the determinants of Ct values at the time of test and, for symptomatic individuals, as a

²⁵ function of the time since symptoms, in data from 292284 patients tested by a large private laboratory

²⁶ in the community in France, from 14 June 2021 to 30 July 2021 in three regions (Bretagne, Île-de-

27 France, Provence-Alpes-Côte d'Azur). These data include information on the result of the PCR test,

²⁸ the associated Ct value, the patient's self-reported vaccine status (whether fully vaccinated since at

²⁹ least two weeks, or not), whether the patient has been symptomatic and the time since the onset of

³⁰ symptoms. Positive tests were screened for the L452R mutation, which characterizes the Delta variant

³¹ (9343 positive tests with mutation information). In the case of multiple tests per individual, we kept

the last negative test if there were no positive tests, and the first positive test otherwise.

³³ Consistent with the French vaccination campaign, vaccinated individuals are on average older than

³⁴ non-vaccinated patients in our dataset (12 years older). The proportion of vaccinated individuals in

 $_{\tt 35}$ the dataset (24%) is lower than in the community (47.5% by 10 July 2021), reflecting the fact that the

³⁶ data are not surveillance-based.

³⁷ Reasons for testing may vary between vaccinated and non-vaccinated individuals. This may especially

³⁸ be the case since France introduced a "sanitary passport," requiring a proof of either full vaccination

 $_{39}$ or a negative test for specific events, which may artificially inflate the proportion of negative tests

 $_{\rm 40}$ $\,$ among non-vaccinated individuals. Conversely, vaccinated individuals may get tested only if they have

⁴¹ good reasons to suspect an infection; these reasons may also vary if symptoms differ depending on the

42 infecting variant.

We compared the cycle threshold (Ct; targeted at gene RdRp) values of the PCR of positive tests 43 depending on vaccine status, the presence of symptoms, and the infecting variant (Delta: presence of 44 the L452R mutation), for the 8437 individuals for which all pieces of information are available. The 45 Ct is the number of PCR cycles needed to detect a target; it is negatively correlated with viral load. 46 We find that the presence of symptoms is associated with significantly lower Ct values (ANOVA; -2.7 47 Ct [-3, -2.5]; adjusted p < 1e-6 (Tukey's Honest Significant Difference)). An infection with the Delta 48 variant is also associated with lower Ct values in these data (-6.7 Ct [-7.1, -6.3]; adjusted p < 1e-6)); 49 note that age of infection is not controlled for here, but will be later on. Comparing vaccinated and 50 non-vaccinated individuals, we find that vaccinated individuals have significantly higher Ct values for 51 both Delta and non-Delta asymptomatic infections (1.7 [1, 2.3] Ct difference; adjusted p < 1e-6), but 52 that the differences are not significant for symptomatic infections (p = 0.8). For non-Delta variants, 53 this result may be due to too small a sample size (only N = 18 vaccinated symptomatic individuals 54 infected with non-Delta). 55

⁵⁶ Ct values also depend on the age of infection of tested individuals. It is therefore useful to control

57 for age of infection, especially when comparing Ct values of variants with different epidemiological

⁵⁸ dynamics, ^{13,16} as was the case for the Delta (increasing numbers of infections) and Alpha (decreasing

⁵⁹ numbers of infections) in the early summer in France. To this end, we add time since symptoms onset

- ⁶⁰ as a continuous variable in the linear model. We find that the Delta variant has Ct at day of symptoms
- ⁶¹ -3.32 [-4.38, -2.25] lower than non-Delta (Alpha) (p < 1e-6, N = 3439). The slope of Ct as function of
- ⁶² time is 0.6 [0.54, 0.66] per day for Delta and 0.92 [0.73, 1.1] for non-Delta variants (*p* < 1e-6). Vaccine
- status does not significantly alter the outcomes, whether regarding the Ct at symptom onset (p = 0.256)
- $_{\rm 64}$ $\,$ or the slope of Ct as function of time since symptoms (p = 0.947) and was therefore not included in the
- 65 final model.
- ⁶⁶ Limitations of our study stem from the way the data were collected: this is a community-based
- ⁶⁷ study. Reasons for seeking a PCR test are unknown and may vary among individuals and across time.
- ⁶⁸ Symptom and vaccine information are self-reported. Yet our dataset is unique for France, because
- ⁶⁹ variant information and vaccine status data have not been linked yet in public datasets, and Ct values
- ⁷⁰ are not reported at the national level (only positive/negative test results are). Our results are in line with
- ⁷¹ a retrospective cohort study which found lower Ct values with Delta and longer duration of infection
- ⁷² with low Ct.⁵ Regarding vaccine-breakthroughs, our results confirm studies finding similar Ct values
- ⁷³ among fully vaccinated individuals and those who were not, with the majority of infections being due
 ⁷⁴ to Delta.^{8,9}
- ⁷⁵ Another limitation of our dataset is the lack of longitudinal data (in Figure 2, each point corresponds
- ⁷⁶ to a single patient). A recent study in Singapore found similar Ct values among vaccinated and
- ⁷⁷ unvaccinated individuals infected by Delta, at the time of diagnosis or of symptom onset.¹¹ After a week
- ⁷⁸ however, Ct values increased faster (i.e. viral load declined faster) among vaccinated individuals than
- ⁷⁹ unvaccinated individuals, even after excluding asymptomatic individuals (personal communication).¹¹
- 80 With transmission occurring early in infection, this delayed differential decrease is expected not to
- ⁸¹ have much of an impact on relative transmissibility.
- ⁸² Ct values are linked to viral load, and viral load has been shown to be positively associated with
- ⁸³ probability of transmission in household contacts but there is also high inter-individual variation,
- 84 and transmission from individuals with high Ct values is possible. 17,18 In spite of these limitations, our
- 85 confirmatory results indicate that epidemic control may require similar measures for symptomatic
- ⁸⁶ PCR-positive vaccinated individuals as non-vaccinated infected individuals, and that it is important to
- ⁸⁷ not to stop testing vaccinated individuals.

Acknowledgements

We thank Mircea Sofonea for critical comments on a previous version of the manuscript. FB was funded by a Momentum grant from the Centre National de la Recherche Scientifique. FD was funded by grant ANR-19-CE45-0009-01 from Agence Nationale de la Recherche.


References

 Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Eurosurveillance [Internet]. 2021 [cited 2021 Jul 18];26. Available from: https://www.eurosurveillan ce.org/content/10.2807/1560-7917.ES.2021.26.24.2100509

- Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Mishra S, et al. SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough [Internet]. In Review; 2021 Jun [cited 2021 Aug 3]. Available from: https://www.researchsquare.com/article/rs-637724/v1
- Alizon S, Haim-Boukobza S, Foulongne V, Verdurme L, Trombert-Paolantoni S, Lecorche E, et al. Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021. Eurosurveillance [Internet]. 2021 [cited 2021 Jul 18];26. Available from: https://www.eurosurveillance.org /content/10.2807/1560-7917.ES.2021.26.28.2100573
- Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada [Internet]. Infectious Diseases (except HIV/AIDS); 2021 Jul [cited 2021 Aug 3]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.07.05.21260050
- 5. Ong SWX, Chiew CJ, Ang LW, Mak T-M, Cui L, Toh MPH, et al. Clinical and Virological Features of SARS-CoV-2 Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). SSRN Electronic Journal [Internet]. 2021 [cited 2021 Aug 3]; Available from: https://www.ssrn.com/abstract=3861566
- Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness. The Lancet [Internet]. 2021 [cited 2021 Jul 18];397:2461–2. Available from: https://linkinghub.elsevier.com/retrieve/pii/S01 40673621013581
- Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine [Internet]. 2021 [cited 2021 Aug 3];NEJMoa2108891. Available from: http://www.nejm.org/doi /10.1056/NEJMoa2108891
- 8. Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021. MMWR Morbidity and Mortality Weekly Report [Internet]. 2021 [cited 2021 Aug 2];70. Available from: http://www.cdc.gov/mm wr/volumes/70/wr/mm7031e2.htm?s_cid=mm7031e2_w
- England PH. SARS-CoV-2 variants of concern and variants under investigation in England. Technical Briefing 16 [Internet]. 2021 Jun. Available from: https://assets.publishing.service.gov. uk/government/uploads/system/uploads/attachme%20nt_data/file/994997/Variants_of_C oncern_VOC_Technical_Briefing_16.pdf
- Elliott P, Haw D, Wang H, Eales O, Walters CE, Ainslie KEC, et al. REACT-1 round 13 final report: Exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021 [Internet]. 2021 Aug [cited 2021 Aug 9]. Available from: https://spiral.imperial.ac.uk/bitstream/10044/1/90800/2/react1_r13_final_p reprint_final.pdf
- 11. Chia PY, Ong S, Chiew CJ, Ang LW, Chavatte JG, Mak TM, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: A multi-center cohort study [Internet]. Infectious Diseases (except HIV/AIDS); 2021 Jul [cited 2021 Aug 2]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.07.28.21261295

- 12. Alizon S, Selinger C, Sofonea MT, Haim-Boukobza S, Giannoli J-M, Ninove L, et al. Epidemiological and clinical insights from SARS-CoV-2 RT-PCR cycle amplification values [Internet]. Infectious Diseases (except HIV/AIDS); 2021 Mar [cited 2021 Aug 9]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.03.15.21253653
- Hay JA, Kennedy-Shaffer L, Kanjilal S, Lennon NJ, Gabriel SB, Lipsitch M, et al. Estimating epidemiologic dynamics from cross-sectional viral load distributions. Science [Internet]. 2021 [cited 2021 Jul 18];373:eabh0635. Available from: https://www.sciencemag.org/lookup/doi/10.1126/science.abh0635
- Cosentino G, Bernard M, Ambroise J, Giannoli J-M, Guedj J, Débarre F, et al. SARS-CoV-2 viral dynamics in infections with Alpha and Beta variants of concern in the French community. Journal of Infection [Internet]. 2021 [cited 2021 Aug 9];S0163445321003741. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0163445321003741
- Althaus CL, Baggio S, Reichmuth ML, Hodcroft EB, Riou J, Neher RA, et al. A tale of two variants: Spread of SARS-CoV-2 variants Alpha in Geneva, Switzerland, and Beta in South Africa [Internet]. Epidemiology; 2021 Jun [cited 2021 Jun 18]. Available from: http://medrxiv.org/lookup/doi/10. 1101/2021.06.10.21258468
- Hay JA, Kennedy-Shaffer L, Mina MJ. Viral loads observed under competing strain dynamics [Internet]. Epidemiology; 2021 Jul [cited 2021 Aug 2]. Available from: http://medrxiv.org/look up/doi/10.1101/2021.07.27.21261224
- Marc A, Kerioui M, Blanquart F, Bertrand J, Mitjà O, Corbacho-Monné M, et al. Quantifying the relationship between SARS-CoV-2 viral load and infectiousness [Internet]. Epidemiology; 2021 May [cited 2021 Aug 9]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.05.07.21 256341
- Lyngse FP, Mølbak K, Træholt Franck K, Nielsen C, Skov RL, Voldstedlund M, et al. Association between SARS-CoV-2 Transmissibility, Viral Load, and Age in Households [Internet]. Epidemiology; 2021 Mar [cited 2021 Aug 9]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021. 02.28.21252608

Bigures



⁸⁹ Figure 1: Distributions of Ct values, according to vaccine status (light: unvaccinated, dark: vaccinated),

⁹⁰ infecting variant (orange: non-Delta, purple: Delta) and whether the individual was symptomatic

91 (left: asymptomatic at least until the test, right: symptomatic). The widths of the violin plots reflect

⁹² the number of tests; points and arrows represent predicted values and confidence intervals. "***"

⁹³ means that the corresponding comparison of unvaccinated and vaccinated individuals is statistically

⁹⁴ significant with p < 0.001.




Figure 2: Regression of Ct value against time since symptoms, for symptomatic individuals, depending
on vaccine status and infecting variant. The lines are the predicted values, the shaded areas the
confidence intervals. The vaccination effect was not significant and therefore removed from the final

98 model.

99 Appendix

100 Variables

name	type	description
sympf	factor (0, 1)	Whether the individual is fully vaccinated (1) or not (0)
deltaf	factor (0, 1)	Whether the L452R is detected (1) or not (0)
vacf	factor (0, 1)	Whether the individual is fully vaccinated (1) or not (0)
Ct	numeric	Ct value, RdRp gene
tSS	numeric	Time since symptom onset (days)

101 Model for Figure 1

mdlAov\$call

```
## aov(formula = Ct ~ vacf * sympf * deltaf, data = tmp)
102
   summary(mdlAov)
                           Df Sum Sq Mean Sq F value
   ##
                                                          Pr(>F)
103
                                  351
                                          351
                                                 12.108 0.000505 ***
   ## vacf
                             1
104
   ## sympf
                             1
                                15200
                                        15200 524.896 < 2e-16 ***
105
   ## deltaf
                                32358
                                       32358 1117.379 < 2e-16 ***
                            1
106
                                          775
                                                 26.766 2.35e-07 ***
   ## vacf:sympf
                                  775
                            1
107
   ## vacf:deltaf
                                          144
                                                 4.970 0.025819 *
                            1
                                  144
108
   ## sympf:deltaf
                                  359
                                          359 12.412 0.000429 ***
                            1
109
   ## vacf:sympf:deltaf
                                  227
                                           227
                                                 7.837 0.005130 **
                             1
110
   ## Residuals
                         8429 244096
                                           29
111
   ## ---
112
   ## Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
113
   thsd
   ##
        Tukey multiple comparisons of means
114
           95% family-wise confidence level
   ##
115
   ##
116
   ## Fit: aov(formula = Ct ~ vacf * sympf * deltaf, data = tmp)
117
   ##
118
   ## $vacf
119
   ##
                diff
                           lwr
                                     upr
                                              p adj
120
   ## 1-0 0.6470032 0.2825148 1.011492 0.0005046
121
   ##
122
   ## $sympf
123
   ##
                diff
                           lwr
                                      upr p adj
124
   ## 1-0 -2.726566 -2.960009 -2.493124
                                               0
125
   ##
126
```

\$deltaf 127 diff ## lwr upr p adj 128 ## 1-0 -6.72394 -7.121566 -6.326314 0 129 ## 130 ## \$`vacf:sympf` 131 ## diff lwr upr p adj 132 ## 1:0-0:0 1.6816459 1.0341760 2.3291159 0.0000000 133 ## 0:1-0:0 -2.5080529 -2.8335307 -2.1825750 0.0000000 134 ## 1:1-0:0 -2.7595748 -3.4541112 -2.0650384 0.0000000 135 ## 0:1-1:0 -4.1896988 -4.8526381 -3.5267595 0.0000000 136 ## 1:1-1:0 -4.4412207 -5.3445110 -3.5379303 0.0000000 137 ## 1:1-0:1 -0.2515219 -0.9605014 0.4574576 0.7986775 138 ## 139 ## \$`vacf:deltaf` 140 ## diff lwr p adj upr 141 ## 1:0-0:0 2.0758433 0.4153934 3.736293 0.0072293 142 ## 0:1-0:0 -6.5769166 -7.1265213 -6.027312 0.0000000 143 ## 1:1-0:0 -5.9746925 -6.6780558 -5.271329 0.0000000 144 ## 0:1-1:0 -8.6527600 -10.2374675 -7.068052 0.0000000 145 ## 1:1-1:0 -8.0505358 -9.6949058 -6.406166 0.0000000 ## 1:1-0:1 0.6022242 0.1033012 1.101147 0.0104180 147 ## 148 ## \$`sympf:deltaf` 149 ## diff lwr upr p adj 150 ## 1:0-0:0 -3.824406 -5.040470 -2.608343 0 151 ## 0:1-0:0 -7.225312 -7.822622 -6.628002 0 152 ## 1:1-0:0 -9.324285 -9.933266 -8.715303 0 153 ## 0:1-1:0 -3.400906 -4.500778 -2.301033 0 154 ## 1:1-1:0 -5.499879 -6.606133 -4.393624 0 155 ## 1:1-0:1 -2.098973 -2.417982 -1.779963 0 156 ## 157 158 ## \$`vacf:sympf:deltaf` diff ## lwr upr p adj 159 ## 1:0:0-0:0:0 4.0748024 1.8402263 6.30937863 0.0000009 160 ## 0:1:0-0:0:0 -3.1720965 -4.6903764 -1.65381653 0.0000000 161 ## 1:1:0-0:0:0 -5.0857054 -8.9932302 -1.17818060 0.0020482 162 ## 0:0:1-0:0:0 -6.9645855 -7.7063452 -6.22282583 0.0000000 163 ## 1:0:1-0:0:0 -5.5406910 -6.5774897 -4.50389237 0.0000000 ## 0:1:1-0:0:0 -8.8873726 -9.6453033 -8.12944188 0.0000000 165 ## 1:1:1-0:0:0 -9.0238193 -10.0823280 -7.96531060 0.0000000 166 ## 0:1:0-1:0:0 -7.2468989 -9.7636751 -4.73012268 0.0000000 167 **##** 1:1:0-1:0:0 -9.1605078 -13.5534270 -4.76758868 0.0000000 168 ## 0:0:1-1:0:0 -11.0393880 -13.1792936 -8.89948235 0.0000000 169 170 **##** 1:0:1-1:0:0 -9.6154935 -11.8746836 -7.35630334 0.0000000

171	##	0:1:1-1:0:0	-12.9621750	-15.1077397	-10.81661041	0.0000000
172	##	1:1:1-1:0:0	-13.0986217	-15.3678571	-10.82938634	0.0000000
173	##	1:1:0-0:1:0	-1.9136089	-5.9890944	2.16187654	0.8466421
174	##	0:0:1-0:1:0	-3.7924891	-5.1676397	-2.41733844	0.0000000
175	##	1:0:1-0:1:0	-2.3685946	-3.9228736	-0.81431555	0.0001056
176	##	0:1:1-0:1:0	-5.7152761	-7.0992165	-4.33133582	0.0000000
177	##	1:1:1-0:1:0	-5.8517228	-7.4205671	-4.28287852	0.0000000
178	##	0:0:1-1:1:0	-1.8788802	-5.7330487	1.97528842	0.8194703
179	##	1:0:1-1:1:0	-0.4549857	-4.3766383	3.46666698	0.9999686
180	##	0:1:1-1:1:0	-3.8016672	-7.6589806	0.05564621	0.0567588
181	##	1:1:1-1:1:0	-3.9381139	-7.8655620	-0.01066581	0.0488069
182	##	1:0:1-0:0:1	1.4238945	0.6109881	2.23680092	0.000031
183	##	0:1:1-0:0:1	-1.9227871	-2.3231923	-1.52238184	0.0000000
184	##	1:1:1-0:0:1	-2.0592338	-2.8996539	-1.21881362	0.0000000
185	##	0:1:1-1:0:1	-3.3466816	-4.1743701	-2.51899298	0.0000000
186	##	1:1:1-1:0:1	-3.4831282	-4.5926552	-2.37360130	0.0000000
187	##	1:1:1-0:1:1	-0.1364467	-0.9911733	0.71827990	0.9997296

188 Model for Figure 2

```
Full model
189
   mdl$call
190 ## lm(formula = Ct ~ vacf * deltaf * tSS, data = dat.nodupl)
   car::Anova(mdl)
   ## Anova Table (Type II tests)
191
   ##
192
   ## Response: Ct
193
   ##
                       Sum Sq Df F value
                                               Pr(>F)
194
   ## vacf
                           27
                                 1
                                     1.2884 0.256427
195
   ## deltaf
                         3192
                                 1 152.3081 < 2.2e-16 ***
196
                                 1 452.6392 < 2.2e-16 ***
   ## tSS
                        9487
197
   ## vacf:deltaf
                            5
                                 1
                                     0.2289 0.632364
198
   ## vacf:tSS
                            0
                                   0.0044 0.947141
                                 1
199
                                 1 10.0434 0.001542 **
   ## deltaf:tSS
                         211
200
   ## vacf:deltaf:tSS
                         44
                                 1 2.1114 0.146299
201
   ## Residuals
                       71911 3431
202
   ## ---
203
   ## Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
204
  Reduced model with significant effect only (used for the Figure)
205
   mdl1$call
206 ## lm(formula = Ct ~ deltaf + tSS + deltaf * tSS, data = dat.nodupl)
   car::Anova(mdl1)
   ## Anova Table (Type II tests)
207
   ##
208
   ## Response: Ct
209
   ##
                 Sum Sq Df F value
                                         Pr(>F)
210
                   3231
   ## deltaf
                          1 154.156 < 2.2e-16 ***
211
212 ## tSS
                  9512 1 453.905 < 2.2e-16 ***
  ## deltaf:tSS 228
                           1 10.872 0.0009863 ***
213
   ## Residuals 71987 3435
214
   ## ---
215
```

216 ## Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1